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tries use the European Directive (ED) 2001/20/EC to govern all
research (e.g. Germany regional EC), others are in an “evolving
process” of coming into “adapted” compliance with the ED (e.g.
France); and others have their own independent regulations that
are less accessible (e.g. Saudi Arabia). Each country has varying
data protection legislation. CONCLUSIONS: For some, regula-
tory approvals are believed to be easier to acquire from disparate
regulatory bodies when no intervention is under study. However,
investigators cautioned that their various regulatory authorities
do not support natural history studies if they appear to be “large
cheap databases” driven by outside countries. More support for
such studies is likely if the natural history data serves as an
untreated control arm when treatments begin to be tested.
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OBJECTIVES: To investigate the relationship between differing
assumptions regarding the basis of placebo effects and estimates
of cost-effectiveness in non-linear models. METHODS:
Responses to placebos observed in randomized controlled trials
have a variety of mechanisms including: a “subject-expectancy”
effect speciﬁc to the experimental situation; a “subject-
expectancy” effect generalisable to a clinical situation; and a
“regression to the mean” effect arising from natural variation. If
the placebo response in a trial with placebo and active treatment
responses of RPLCB and RTX arose from a trial speciﬁc “subject-
expectancy”, we would expect to see no response to placebo and
RTX—RPLCB response to treatment in a clinical situation. If the
placebo response arose from generalisable “subject-expectancy”
or natural variation, we would expect to see RPLCB response to
placebo and RTX response to treatment in a clinical situation.
Estimates of cost-effectiveness from a simple model of an
epilepsy treatment, where the expected costs and effects were
non-linear with respect to response rate, were obtained under
these differing assumptions. RESULTS: The icer assuming a trial
speciﬁc “subject-expectancy” was ≤14,000 and assuming a
general “subject-expectancy” or natural variation placebo effect
was ≤20,000. CONCLUSIONS: For non-linear models the 
incremental cost-effectiveness ratios and the identiﬁcation of
optimum treatment choice may be sensitive to assumptions
regarding the placebo response mechanism. Even where the
analysis is based on the results of actively controlled trials,
responses may still include an element of placebo effect and the
incremental cost-effectiveness ratios may be sensitive to assump-
tions regarding the basis of this effect. We should also consider
that the placebo effect may differ over different dimensions of
response, such as initial probability and duration, and also care-
fully consider the appropriate estimation of the “no-treatment”
comparator response rates in clinical situations where the use of
placebos is not permissible.
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OBJECTIVES: Despite evidence on the cost-effectiveness of clin-
ical guidelines, patients and health care providers do not adhere
to guideline recommendations. Implementation strategies aim to
change guideline adherence but cost money to enact. As health
care resources are limited, it becomes increasingly important to
determine whether investing in guideline implementation is
worthwhile. METHODS: We developed a model to calculate the
total net monetary beneﬁts of guideline implementation for an
eligible patient population. By combining evidence on guidelines,
current practice and implementation strategies our model allows
the determination of the total potential to invest in guideline
implementation and the mutual comparison of implementation
strategies. We illustrated the use of our model with a hypothet-
ical example and examined the extent to which alternative mod-
elling assumptions inﬂuence the efﬁcient allocation of scarce
resources. RESULTS: Through illustration of the use; our model,
we demonstrated the inﬂuence of the threshold value ë, the base-
line guideline adherence and the patient population size on the
total guideline implementation investment potential and the total
net monetary beneﬁts of guideline implementation. CONCLU-
SIONS: Using a total net monetary beneﬁts approach, our model
overcomes problems with the use of policy cost-effectiveness
ratios and allows the incorporation of uncertainty surrounding
evidence on guidelines, current practice and implementation
strategies. Moreover, our model provides simple and useful tool
to examine the value for money of guideline implementation and
inform policy decisions about efﬁcient allocation of scarce
resources.
PMC9
A REVIEW OF FACTORS AFFECTING THERAPEUTIC
COMPLIANCE
Jin J, Li SC
National University of Singapore, Singapore, Singapore
OBJECTIVE: To explore the deﬁnition of therapeutic compli-
ance and evaluate the most common factors causing therapeutic
non-compliance. METHODS: A qualitative review was under-
taken by a literature search of the Medline database from 1970
to 2005. The following key words were used: treatment refusal,
patient compliance, patient dropouts, factors, predictors and
determinants. RESULTS: A total of 7372 articles were retrieved
by the literature review process. From the literature review, the
most commonly accepted deﬁnition of therapeutic compliance is
patient’s behaviors (in terms of taking medication, following
diets, or executing life style changes) coincide with health care
providers’ recommendation for health and medical advice. 
The preliminary evaluation revealed a number of factors that
contributed to therapeutic noncompliance. These factors
include:Patient-centered factors: demographic factors (age,
gender, ethnicity, education background , marriage status ),
patients’ beliefs, motivation and attitude about The rapy, patient-
prescriber relationship, health literacy, patients’ education, phys-
ical difﬁculties, smoking and alcohol intake, poor quality of life,
forgetfulness, a history of noncompliance.Therapy-related
factors: treatment complexity, duration of the treatment period,
medication side effects, degree of behavioral change required.
Social and economic factors: cost, income, social support, health
care system factors, and characteristics of the disease. Broadly
speaking, factors related to poor therapeutic compliance can be
categorized to intentional factors and non-intentional factors.
They are complicated and not fully predictive. CONCLUSION:
From the review, it would appear that there are numerous studies
on the issue of therapeutic noncompliance, the deﬁnition of ther-
apeutic compliance is adequately addressed and generally
accepted by the clinical communities. Regarding reasons for ther-
apeutic non-compliance, there are many factors being reported
and studied over the years, but the evidence is sometimes con-
